Pt # | Sites of disease | Prior therapy | HER2/neu test | HER2/neu therapy | Concurrent therapy | Duration of therapy (weeks) | Overall survival (weeks) | Best response |
---|---|---|---|---|---|---|---|---|
1 | Bone, liver | Nil | IHC 3+ | Trastuzumab | Gemcitabine, cisplatin | 7 | 20 | SD |
2 | Peritoneum, lung, liver | Gemcitabine + cisplatin, FOLFIRI + erbitux | Mutation (NGS) V777L | Lapatinib | Sirolimus | 15 | 19 | MR |
3 | Retroperitoneal LN, liver | Nil | FISH amplification | Trastuzumab | Nil | 38 | 113 | CR |
4 | Liver | Gemcitabine + cisplatin, capecitabine, FOLFOX | ERBB2 NGS amplification | Trastuzumab | Gemcitabine + irinotecan | 40 | 62 | PR |
5 | Liver, LN | Gemcitabine + cisplatin | ERBB2 NGS amplification | Trastuzumab | FOLFOX capecitabine | 92 | 92 | PR |
6 | Sternum, pleura, lung | Gemcitabine, capecitabine | AMPLIFIED (FISH) | Trastuzumab | Â | 168 | 178 | PR |
7 | Retroperitoneal LN, celiac LN | Nil | AMPLIFIED (FISH) | Trastuzumab | Gemcitabine + cisplatin | 22+ | 22+ | PR |
8 | Retroperitoneal LN, supraclavicular LN | Gemcitabine + capecitabine, gemcitabine + cisplatin, pazopanib, dovitinib | ERBB2 NGS amplification | Trastuzumab + pertuzumab | Nil | 8+ | 8+ | SD |
9 | Lungs, brain | Gemcitabine + cisplatin radiation | IHC 3+ | Trastuzumab | Paclitaxel capecitabine | 72 | 96+ | PR |